Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth formulary coverage & PA update | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    2026 Formulary (XCHG) — Drug List, Tiers, and Utilization Management

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the EmblemHealth formulary listing covered drugs, tiers, and utilization management rules (e.g., prior authorization, step therapy, quantity limits) for members and providers in the plan. It applies to members using the XCHG formulary as of May 1, 2026.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Formulary (XCHG) — Drug List, Tiers, and Utilization Management
    Policy CodePolicy N/A
    Change TypeAdministrative update (no material clinical changes)
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a product is flagged 'PA' and document medical necessity, dosing, and requested quantity to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-05-01formulary effective/updated date
    AC, PA, QL, ST, LD, SPutilization management abbreviations used
    Home deliverymail-order/home delivery option
    ~120drug or vaccine line items listed
    PAmany products require

    Formulary Coverage Criteria

    Product-level coverage constraints

    Coverage is product-specific and subject to the Requirements/Limits listed for each product.

    Formulary coverage note: Products are assigned a Drug Tier and may include one or more Requirements/Limits flags (e.g., PA, QL, LD, SP, AC) that govern coverage. Providers must follow the per-product Requirements/Limits shown in the formulary listing.

    No indication-specific clinical inclusion/exclusion criteria are provided in this formulary segment.

    Formulary controls

    Coverage and dispensing controls are indicated on each drug or vaccine line as shown in the Requirements/Limits field.

    Per-product controls: Each listed product includes a Drug Tier and may include one or more flags in the Requirements/Limits field: PA (prior authorization), QL (quantity limit with specified amount and time period), LD (loading/limited distribution), SP (specialty pharmacy), AC (administrative coverage). Coverage and dispensing must comply with the exact flags and QL values shown per line item.

    See individual line items for exact QL numeric values, LD/SP channel requirements, and AC vaccine administrative flags.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Formulary (XCHG) — Drug List, Tiers, and Utilization Management
    Policy CodePolicy N/A
    Change TypeAdministrative update (no material clinical changes)
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a product is flagged 'PA' and document medical necessity, dosing, and requested quantity to avoid claim denial.
    SourceLink
    On This Page
    Formulary Coverage CriteriaFormulary Listings and Code TablesActions Providers Must TakeQuantity Limits and ExamplesDispensing Channel and Site-of-Care NotesBiosimilars and Related NotesAbbreviations and DefinitionsStep Therapy Rules and NotesPolicy BackgroundPolicy Revision History

    Coverage stance

    Products listed are subject to the Requirements/Limits specified on each line (examples include PA, LD, QL, SP).

    Per-product requirements: Coverage for a given product requires compliance with its per-line Requirements/Limits (for example: obtain prior authorization when 'PA' is shown; dispense within numeric QL limits; use specialty or limited distribution channels when 'SP' or 'LD' are indicated).

    This formulary segment does not provide indication-specific medical necessity rules; those are implemented through the plan's PA or clinical review processes referenced by the flags.

    Administrative coverage controls

    Coverage and administrative controls are indicated per drug entry using these required flags when present.

    Administrative requirements: If a drug entry shows any of the following flags in Requirements/Limits, those administrative conditions must be met for coverage: PA (prior authorization), QL (quantity limit with amount/time period), LD (limited distribution or loading dose), SP (specialty pharmacy), AC (administrative coverage/access criteria).

    Entries in the document are primarily administrative; clinical PA criteria (if required) are managed via the plan's prior authorization process.

    Formulary administrative criteria

    Coverage and administrative controls for listed outpatient cardiovascular drugs are shown per-line with required flags where applicable.

    Formulary entries: Each cardiovascular drug entry lists the drug name/formulation, Drug Tier, and any Requirements/Limits (examples in this class include QL values such as 210 tablets/30 days for multiple beta‑blocker entries, PA/LD/SP flags for selected specialty cardiovascular agents, and PA+QL for agents like NEXLETOL/NEXLIZET and REPATHA).

    Clinical indications and diagnosis-level medical necessity criteria are not included in this formulary excerpt; follow the listed administrative flags and the plan's PA process for clinical review.

    Formulary coverage conditional on utilization controls

    Coverage is conditional on satisfying the utilization controls shown for each product.

    Formulary coverage conditions: Coverage for individual products is provided only when plan utilization controls are satisfied: prior authorization must be obtained for entries marked 'PA'; dispensed quantity must not exceed the numeric QL for the product (e.g., REPATHA QL 6 syringes/28 days; VASCEPA QL 120–240 capsules/30 days); limited or specialty distribution requirements (LD/SP) must be observed for applicable products.

    Exact clinical PA criteria are managed through the payer's authorization process and are not enumerated in this formulary listing.

    Please see the member’s Certificate of Coverage for plan-specific details. Not all drugs in this formulary are paid for by all drug benefit plans; coverage depends on the member’s specific benefits and certificate. Check the member ID card or contact member services for eligibility, coverage, and cost-share questions.

    This section does not include explicit exclusion statements. Instead, each line-item shows administrative controls (for example: PA = prior authorization, LD = limited distribution, QL = quantity limit, SP = specialty pharmacy) that must be met for coverage as noted next to the product.

    The content here is a formulary list of vaccines and related products showing tier assignments and Requirements/Limits flags (for example, many vaccines are marked AC for administrative coverage). No explicit exclusion statements are provided in these lines.

    This formulary segment lists product-level utilization controls (e.g., PA, QL, LD, SP) for each drug line. The document does not present separate clinical exclusion criteria; failure to meet a listed administrative requirement or exceeding a stated QL may result in non‑coverage per plan rules.

    The entries in these chunks identify Requirements/Limits such as PA and numeric QL values for listed products but do not designate any items as explicitly "Not Medically Necessary." Coverage determinations therefore follow the administrative flags shown per line item.

    No clinical exclusion criteria are specified in this section. Coverage for each listed product is governed by the administrative Requirements/Limits shown (for example, PA, QL, LD, SP), and providers must satisfy those conditions for the plan to consider payment.

    This excerpt does not list clinical exclusions. Some formulations do not show Requirements/Limits, which implies standard coverage rules apply; otherwise coverage is conditional on meeting any flags shown (e.g., PA, QL, SP).

    There are no explicit exclusion conditions or items labeled 'Not Medically Necessary' in this excerpt. The listing provides formulary attributes (tier and Requirements/Limits) that govern administrative coverage decisions.

    This excerpt does not identify any products as 'Not Medically Necessary.' Instead, it includes Requirements/Limits flags (for example, PA and numeric QL values) that determine administrative coverage and may lead to denial if unmet.

    No explicit 'Not Medically Necessary' statements are present in these lines. Coverage depends on compliance with the listed administrative controls (e.g., prior authorization or quantity limits) in each product entry.

    This section does not include specific 'Not Medically Necessary' determinations. Where Requirements/Limits are present (such as PA, QL, or SP), those administrative conditions control coverage decisions.

    Formulary Listings and Code Tables

    Formulary Drug Listings (antibiotics excerpt)mixed
    amoxicillin (trihydrate) chew tab 125 mg, 250 mgDrug Tier = 3
    amoxicillin (trihydrate) cap 250 mg, 500 mgDrug Tier = 1
    amoxicillin (trihydrate) for susp 125 mg/5ml, 200 mg/5ml, 250 mg/5mlDrug Tier = 1
    amoxicillin (trihydrate) tab 500 mg, 875 mgDrug Tier = 1
    amoxicillin & k clavulanate for susp various strengths; Augmentin es-600Multiple formulations; Drug Tier = 1 (some formulations Tier = 3)
    penicillin v potassium for soln 125 mg/5ml, 250 mg/5ml; tab 250 mg, 500 mgMix of Tier 3 (solution) and Tier 1 (tabs)
    cefadroxil, cefdinir, cefixime, cefpodoxime, cefprozil, cefuroxime, cephalexinVarious cephalosporins with mixed tiers and requirements
    azithromycin (susp and tabs), clarithromycin, fidaxomicin (Dificid), erythromycinMacrolides and related agents with mixed tiers
    doxycycline, minocycline, omadacycline (NUZYRA - LD), tetracyclineTetracyclines with some limited distribution
    delafloxacin (BAXDELA), ciprofloxacin (CIPRO), levofloxacin, moxifloxacin, ofloxacinFluoroquinolones with mixed tiers
    Tetracyclines & examplesmixed
    NUZYRAomadacycline tosylate tab 150 mg — Drug Tier = 3; Requirements/Limits = LD
    doxycycline hyclatecaps/tabs 20-150 mg — Drug Tier = 1
    minocycline hclcap 50/75/100 mg — Drug Tier = 1
    Fluoroquinolones & examplesmixed
    BAXDELAdelafloxacin meglumine tab 450 mg — Drug Tier = 3
    CIPROciprofloxacin for oral susp/tabs — Drug Tier = 3 (susp), 1 (tabs)
    levofloxacinoral soln 25 mg/ml; tab 250/500/750 mg — Drug Tier = 1
    Aminoglycosides & inhaled aminoglycosinesmixed
    ARIKAYCEamikacin sulfate liposome inhal susp 590 mg/8.4ml — Drug Tier = 3; Requirements/Limits = LD, PA, QL (28 vials/28 days), SP
    TOBI PODHALERtobramycin inhal cap 28 mg — Drug Tier = 3; Requirements/Limits = LD, SP
    TOBRAMYCIN (nebulized)nebulized solution 300 mg/5ml — Drug Tier = 3; Requirements/Limits = SP
    Antimycobacterial and antifungal examplesmixed
    SIRTURObedaquiline fumarate tab 20 mg, 100 mg — Drug Tier = 2; Requirements/Limits = LD, SP
    CRESEMBAisavuconazonium sulfate cap 74.5 mg, 186 mg — Drug Tier = 3; Requirements/Limits = PA
    itraconazole (Sporanox)cap/solution — Drug Tier = 1; Requirements/Limits = QL (120 capsules/30 days) and PA for solution with QL (1200 mls/30 days)
    Antivirals, HIV and HCV combination products and other specialty antiviralsmixed
    APRETUDEcabotegravir im extended release susp 600 mg/3ml — Drug Tier = 2; Requirements/Limits = AC, LD, SP
    BIKTARVYbictegravir-emtricitabine-tenofovir af tabs — Drug Tier = 2; Requirements/Limits = QL (30 tablets/30 days)
    EPCLUSAsofosbuvir-velpatasvir tab/pellet — Drug Tier = 2; Requirements/Limits = PA, QL (28/day), SP
    HARVONIledipasvir-sofosbuvir tab/pellet — Drug Tier = 2; Requirements/Limits = PA, QL (28/28 days), SP
    MAVYRETglecaprevir-pibrentasvir tab/pellet — Drug Tier = 2; Requirements/Limits = PA, QL (84/28 days or 140/28 days), SP
    PAXLOVIDnirmatrelvir + ritonavir pak — Drug Tier = 2; Requirements/Limits = QL (various pack sizes/30 days)
    SOVALDI / SOFOSBUVIRsofosbuvir tab/pellet — Drug Tier = 2; Requirements/Limits = PA, QL (28/28 days), SP
    SUNLENCAlenacapavir sodium tab therapy pack — Drug Tier = 3; Requirements/Limits = LD, QL (4-5 tablets/365 days), SP
    VIREAD / tenofovir disoproxil fumaratetabs 150-300 mg — Drug Tier = 1-2 (varies); Requirements/Limits = QL (30 tablets/30 days)
    Formulary line itemsmixed
    STRIBILDelvitegrav-cobic-emtricitab-tenofovdf tab 150-150-200-300 mg
    SUNLENCAlenacapavir sodium tab/therapy pack 300 mg
    SYMTUZAdarunavir-cobic-emtricitab-tenofov af tab 800-150-200-10 mg
    TIVICAYdolutegravir sodium tab 50 mg
    TRIUMEQabacavir-dolutegravir-lamivudine tab 600-50-300 mg
    VIREADtenofovir disoproxil fumarate tab/powder (various strengths)
    VOSEVIsofosbuvir-velpatasvir-voxilaprevir tab 400-100-100 mg
    XOFLUZAbaloxavir marboxil therapy pack
    YEZTUGO / YEZTUGO (prophylaxis)lenacapavir sodium subcut/tab (prophylaxis)
    zidovudine (Retrovir)zidovudine formulations (cap, syrup, tab)
    1–10 of 17
    1/2
    Vaccine/Formulary Entriesmixed
    VAXNEUVANCEpneumococcal 15-valent conjugate vaccine suspension pref syr 0.5 ml
    VARIVAXvaricella virus vaccine live for injection 1350 pfu/0.5 ml
    VIVOTIFtyphoid vaccine cap delayed release
    YF-VAXyellow fever vaccine for subcutaneous suspension
    ADACELtetanus-diphtheria-acellular pertussis vaccine injection 0.5 ml
    BOOSTRIXtetanus-diphtheria-acellular pertussis vaccine pref syringe 0.5 ml
    Passive immunizing agents / allergen immunotherapymixed
    BEYFORTUSnirsevimab-alip IM solution prefilled syringe 50 mg/0.5 ml, 100 mg/ml — Requirements/Limits = AC, SP
    ENFLONSIAclesrovimab-cfor IM solution prefilled syringe 105 mg/0.7 ml — Requirements/Limits = AC, SP
    PALFORZIApeanut allergen powder-dnfp (multiple level packs listed) — Requirements/Limits = LD, SP
    Antineoplastic / oncology and specialty agentsmixed
    abiraterone acetate 250 mgZytiga — Requirements/Limits = PA, QL (120 tablets/30 days), SP
    abiraterone acetate 500 mgZytiga — Requirements/Limits = PA, QL (60 tablets/30 days), SP
    ALECENSAalectinib HCl cap 150 mg — Requirements/Limits = LD, PA, QL (240 capsules/30 days), SP
    ALUNBRIGbrigatinib tab (initiation pack and strengths) — Requirements/Limits = LD, PA, QL (varies), SP
    BOSULIFbosutinib — Requirements/Limits = LD, PA, QL (various), SP
    BRUKINSAzanubrutinib — Requirements/Limits = LD, PA, QL (various), SP
    CABOMETYXcabozantinib s-malate — Requirements/Limits = LD, PA, QL (30 tablets/30 days), SP
    CPLEX_ANTINEOPLASTICSMultiple antineoplastic agents listed (e.g., palbociclib, imatinib, dasatinib, everolimus, etc.)
    Drug list (no billing codes in this section)mixed
    No codes listed
    Formulary drug entries in this document segmentNDC | mixed
    VORANIGO - vorasidenib tab 40 mgDrug Tier = 2; Requirements/Limits = LD, PA, QL (30 tablets/30 days), SP
    WELIREG - belzutifan tab 40 mgDrug Tier = 3; Requirements/Limits = LD, PA, QL (90 tablets/30 days), SP
    XALKORI - crizotinib cap 200 mg, 250 mgDrug Tier = 2; Requirements/Limits = LD, PA, QL (120 capsules/30 days), SP
    XOSPATA - gilteritinib fumarate tablet 40 mgDrug Tier = 3; Requirements/Limits = LD, PA, QL (90 tablets/30 days), SP
    XPOVIO - selinexor tab therapy packDrug Tier = 3; Requirements/Limits = LD, PA, QL (various), SP
    XTANDI - enzalutamidecaps/tab 40 mg, 80 mg — Drug Tier = varies; Requirements/Limits = LD, PA, QL (varies)
    YONSA - abiraterone acetate micronized tab 125 mgDrug Tier = listed with tier and requirements
    ZEJULA - niraparib tosylate tab 100/200/300 mgDrug Tier = listed with requirements and QL
    ZELBORAF - vemurafenib tab 240 mgDrug Tier = listed with requirements
    ZOLINZA - vorinostat cap 100 mgDrug Tier = listed with requirements
    1–10 of 15
    1/2
    Formulary drug entriesmixed
    TYBLUMElevonorgestrel & ethinyl estradiol chew tab 0.1 mg-20 mcg — Drug Tier = 3
    VELIVETdesogestrel-ethinyl estradiol tab (various strengths) — Drug Tier = 3
    YAZdrospirenone-ethinyl estradiol tab 3-0.02 mg — Drug Tier = 3
    BAQSIMI ONE PACKglucagon nasal powder 3 mg/dose — Drug Tier = 2
    FARXIGAdapagliflozin propanediol tab 5 mg, 10 mg — Drug Tier = 2; Requirements/Limits = QL (30 tablets/30 days)
    MOUNJAROtirzepatide soln auto-injector — Drug Tier = 2; Requirements/Limits = PA, QL (4 pens/180 days or 4 pens/28 days depending on strength)
    OZEMPICsemaglutide soln pen-inj — Drug Tier = 2; Requirements/Limits = PA, QL (1 pen/28 days or 3 pens/28 days depending on strength)
    JANUMET / JANUMET XRsitagliptin-metformin combos — Drug Tier = 2; Requirements/Limits = QL (60 tablets/30 days for JANUMET)
    TRULICITYdulaglutide soln auto-injector — Drug Tier = 2; Requirements/Limits = PA, QL (4 pens/28 days)
    RYBELSUSsemaglutide oral tablets — Drug Tier = 2; Requirements/Limits = PA, QL (30 tablets/180 days or 30/30 depending on strength)
    1–10 of 13
    1/2
    No CPT/HCPCS/ICD-10 codes listed in this sectionmixed
    No codes listed
    Listed drugs and utilization controls (partial list shown in this segment)mixed
    NEXLETOL - bempedoic acid 180 mgRequirements/Limits = PA, QL (30 tablets/30 days)
    NEXLIZET - bempedoic acid-ezetimibe 180-10 mgRequirements/Limits = PA, QL (30 tablets/30 days)
    REPATHA - evolocumab 140 mg/mLRequirements/Limits = QL (6 syringes/28 days)
    VASCEPA - icosapent ethyl 0.5 g and 1 gRequirements/Limits = PA, QL (240 capsules/30 days for 0.5 g; 120 capsules/30 days for 1 g)
    ENTRESTO - sacubitril-valsartanRequirements/Limits = PA, QL (240 capsules/30 days) for sprinkle; standard tabs listed separately
    CAMZYOS - mavacamtenRequirements/Limits = LD, PA, QL (30 capsules/30 days), SP
    TYVASO - treprostinil inhalation solutionRequirements/Limits = LD, PA, QL (7 packages/28 days)
    UPTRAVI - selexipagRequirements/Limits = LD, PA, QL (60 tablets/30 days), SP
    VYNDAMAX - tafamidis 61 mgRequirements/Limits = PA, QL (30 capsules/30 days), SP
    WINREVAIR - sotatercept-csrkRequirements/Limits = LD, PA, QL (1 kit/21 days), SP
    1–10 of 17
    1/2
    N/A - drug list (no procedure/diagnosis codes in this segment)mixed
    No codes listed
    NDC/Codes not providedmixed
    No codes listed
    No explicit CPT/HCPCS/ICD-10/NDC codes in this excerptmixed
    No codes listed

    Actions Providers Must Take

    Prior Authorization

    Obtain Prior Authorization for Drugs Marked 'PA'

    Some listed drugs require prior authorization (PA) before the plan will pay; entries with 'PA' in the Requirements/Limits field indicate this requirement and must have approval obtained prior to dispensing.

    Prior Authorization

    Obtain PA and Respect QL/LD/SP Flags

    When a product's Requirements/Limits includes PA, QL, LD, or SP, providers must obtain prior authorization where shown, and ensure the dispensed quantity and distribution channel comply with the listed quantity limits (QL) and limited/specialty distribution (LD/SP).

    • Adhere to QL numeric limits shown (e.g., tablets/pens per days/period).
    • Use designated specialty or limited distribution channels when LD or SP is flagged.
    Prior Authorization

    Obtain PA When Indicated for Specific Products

    Providers must obtain prior authorization for products listed with 'PA' in the Requirements/Limits field (examples in the formulary include STRIBILD, VOSEVI, and linezolid suspension); do not dispense without the required authorization.

    • STRIBILD: Requirements/Limits include PA / QL as noted.
    • VOSEVI: Requirements/Limits = PA, QL (28 tablets/28 days).
    • Linezolid suspension: listed with Requirements/Limits entries indicating PA where shown.
    Prior Authorization

    Secure PA for Specialty and Oncology Agents

    Many specialty and oncology agents are flagged with PA (and often LD and SP); providers must secure prior authorization per the Requirements/Limits before the plan will cover these specialty agents.

    • Examples include multiple antineoplastics and specialty biologics listed with LD/PA/QL/SP flags.
    • Follow specialty program/site-of-care requirements for SP-designated drugs.
    Prior Authorization

    PA Required — Observe LD and QL Conditions

    Prior authorization is required for many listed specialty and branded agents; some entries also specify loading dose (LD) or quantity limits (QL) that must be met — obtain PA and document LD/QL compliance before dispensing.

    • Confirm and document any LD (loading dose) requirements prior to initial dispensing.
    • Ensure requested quantity does not exceed stated QL (e.g., pack or per‑period limits).
    Prior Authorization

    Obtain PA When 'PA' Is Shown

    If 'PA' appears in a product's Requirements/Limits field, providers must obtain prior authorization before the plan will cover the medication; PA is commonly required for higher‑tier and specialty drugs.

    Prior Authorization

    PA Required for GLP‑1 and Related Agents

    Certain GLP‑1 and related agents (e.g., MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY) and other specialty products are listed with PA; providers must submit prior authorization requests for these products as indicated.

    • MOUNJARO: Requirements/Limits = PA, QL (4 pens/180 days or 4 pens/28 days depending on strength).
    • OZEMPIC: Requirements/Limits = PA, QL (1 pen/28 days).
    • TRULICITY: Requirements/Limits = PA, QL (4 pens/28 days).
    Prior Authorization

    PA Required for LD/PA‑Flagged Products

    Products marked 'PA' or 'LD, PA' (for example, ACTHAR, GENOTROPIN, CRENESSITY) require prior authorization; providers must follow the plan's PA process for these limited‑distribution or specialty items.

    • ACTHAR: Requirements/Limits = LD, PA, SP.
    • GENOTROPIN: Requirements/Limits = PA, SP.
    • CRENESSITY: Requirements/Limits include PA and QL as specified.
    Prior Authorization

    PA Required for Selected Formulations (e.g., Liquid/Specialty)

    Certain liquid formulations and specialty products explicitly list 'PA' (examples include propranolol oral solutions, nimodipine oral solutions, and specialty lipid or cardiac agents); obtain prior authorization and document the request.

    • Propranolol oral solutions: Requirements/Limits = PA, QL (2400 mls/30 days and 4800 mls/30 days).
    • NEXLETOL/NEXLIZET and VASCEPA: Requirements/Limits = PA and QL as noted.
    Prior Authorization

    PA Required for Many Formulary Agents

    Numerous products across the formulary require prior authorization (PA) as indicated next to each drug; providers must use the plan's PA process before submitting claims for these drugs.

    Prior Authorization

    Obtain PA for Listed Products in This Segment

    Prior authorization is required for products listed with PA in the Requirements/Limits field (examples in this segment include SYMPROIC, TREMFYA, TRULANCE, VOWST, ZYMFENTRA); obtain PA before dispensing.

    • TREMFYA: Requirements/Limits = PA, QL (1 syringe/28 days), SP.
    • VOWST: Requirements/Limits = LD, PA, QL (12 capsules/365 days), SP.
    Prior Authorization

    PA Required for Specialty/Restricted Drugs

    Specialty or restricted drugs annotated with PA, LD, or SP (for example SUNOSI, WAKIX, AUSTEDO, AVONEX, BETASERON) require prior authorization; providers must secure PA and follow any limited distribution instructions before claim submission.

    • SUNOSI: Requirements/Limits = PA, QL (30 tablets/30 days).
    • WAKIX: Requirements/Limits = LD, PA, QL (60 tablets/30 days).
    Prior Authorization

    PA Required for Specialty/Branded Agents

    Many specialty and branded agents in the formulary require prior authorization as indicated in the Requirements/Limits column; obtain PA and confirm any additional handling (LD/SP) before dispensing.

    Prior Authorization

    PA Required for Numerous Formulary Drugs

    Many formulary drugs (notably specialty biologics, ER opioids, targeted therapies, and migraine/preventive agents) are flagged with PA; providers must obtain prior authorization for these products as listed.

    Step Therapy

    Follow Step Therapy (ST) Before Coverage

    Step therapy (ST) requires trying specified first‑line drugs before other agents will be covered; members or providers may request an exception if the preferred agent is not appropriate.

    • If a drug is marked 'ST' in Requirements/Limits, ensure any required prior trial(s) of first‑line agents are documented or request an exception.
    Note

    No Detailed Step Sequences Provided Here

    No explicit step‑therapy sequences are provided in this formulary excerpt; where 'ST' is not specified, the document does not list step‑by‑step required trials.

    Note

    Follow Specialty Program (SP) Requirements

    Some products include 'SP' (special program) indicators that denote specialty program or site‑specific management; follow the payer's specialty program requirements where SP is flagged.

    • BEYFORTUS, ENFLONSIA, PALFORZIA levels are shown with AC/LD/SP or LD/SP flags indicating specialty program handling.
    Note

    Follow 'AC' Access Criteria for Contraceptives and Similar Items

    Contraceptives and select drug groups may show 'AC' or other access flags indicating plan-specific access criteria; providers should follow payer access/coverage pathways when AC appears.

    • Examples include ANNOVERA and other contraceptive listings with Requirements/Limits = AC.
    Step Therapy

    Adhere to Step Therapy Flags ('ST') Where Shown

    Some products are explicitly marked 'ST' (step therapy) in the Requirements/Limits field (examples include KERENDIA and others); providers must document required prior therapies or obtain an exception.

    • KERENDIA: listed with 'ST' indicating step therapy may be required prior to coverage.
    Step Therapy

    Document Prior Trials for 'ST'‑Flagged Agents

    Some agents are subject to step therapy as noted by 'ST' in Requirements/Limits (examples in the formulary include VELPHORO, FETZIMA, FLUOXETINE DR, TRINTELLIX); ensure prior‑trial requirements are met before coverage.

    • VELPHORO: Requirements/Limits include ST.
    • FETZIMA and TRINTELLIX: Requirements/Limits include QL and ST where specified.
    Step Therapy

    Comply with Step Edits for ST‑Flagged Drugs

    Step edits apply to several products marked 'ST' (examples include FANAPT packs, SECUADO patch, DAYVIGO, BELSOMRA); follow the step therapy requirements noted for each product listing.

    Step Therapy

    Check Step Therapy for Select Agents (NSAIDs/Analgesics)

    Select agents (e.g., certain NSAIDs/analgesics and others) include 'ST' flags indicating step therapy applies; verify required prior therapies before prescribing higher‑tier alternatives.

    • Ketoprofen ER and meclofenamate sodium are examples of agents noted with 'ST'.
    Note

    Contact Member Services for Coverage Questions

    For coverage or questions about drugs not listed or to resolve PA/QL/LD/SP requirements, providers or members may contact EmblemHealth Member Services at 877-793-6253 (TTY 711).

    Billing Rule

    Observe Quantity Limits (QL) When Submitting Claims

    Quantity limits (QL) shown next to many products indicate the maximum covered amount per time period; when submitting claims or PA requests, ensure the requested quantity and days supply comply with the listed QL.

    • Examples: FARXIGA QL 30 tablets/30 days; OZEMPIC QL 1 pen/28 days; REPATHA QL 6 syringes/28 days.
    Documentation Required

    Document Dispensing Channel for LD/QL Items

    Medications marked with 'LD' (limited distribution) or 'LD, PA' may require documentation of the dispensing channel or enrollment in a specialty pharmacy program; providers must document where and how the product will be obtained.

    • Document specialty pharmacy enrollment or designated dispensing site when LD/SP is indicated.
    Documentation Required

    Include Clinical Documentation with PA Requests

    Providers must submit documentation supporting prior authorization requests and must demonstrate dosing consistent with listed quantity limits and any loading dose (LD) specifications when applicable.

    • Include diagnosis, clinical rationale, requested quantity, and days supply when submitting PA requests.
    • Provide evidence of prior therapy where step therapy (ST) is required or an exception rationale if applicable.
    Documentation Required

    Provide Medical Necessity Documentation for PA/QL/LD/SP

    Prescribers must supply documentation of medical necessity and any required supporting information when a product is marked 'PA', 'QL', 'LD', or 'SP' to satisfy the plan's utilization management requirements.

    • Use product‑specific prior authorization forms when available and include indication, prior treatments, and dosing schedule.
    Documentation Required

    Attach Supporting Documentation for PA/QL Requests

    When a product is flagged 'PA', 'QL', or 'LD', prescribers must provide documentation supporting the prior authorization and the requested quantity/days supply; lack of such documentation may lead to denial.

    • For products like NEXLETOL/NEXLIZET/VASCEPA, include diagnosis and requested quantity consistent with QL.
    Denial Risk

    Adhere to Administrative Controls to Avoid Denials

    Use the formulary flags (PA, LD, SP, ST, QL) shown for each product as administrative controls; failure to meet these controls (e.g., missing PA, not using specialty channel, or exceeding QL) may result in claim denial.

    • Verify PA approval and specialty pharmacy dispensing before submitting claims for SP/LD products.
    • Confirm requested quantity is within the listed QL to avoid denial.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Quantity Limits and Examples

    inv-37: Quantity limit examples
    ExamplesQL 28 packets/28 days; QL 30 tablets/30 days; QL 120 capsules/30 days; QL 4–5 tablets/365 days
    ContextQuantity limits are listed per product line in the Requirements/Limits field and specify the maximum units allowed per time period.
    Related flagsQL often appears with PA, LD, or SP on specialty products — e.g., ARIKAYCE = QL (28 vials/28 days) with LD, PA, SP.
    Provider actionPrescriptions exceeding listed QL may be denied; documentation should support requested quantity when PA/QL present.
    Source examplesSee MAVYRET QL (84 tablets/28 days) and STRIBILD QL (28 packets/28 days) for packet/packetized limits.
    inv-38: Quantity limits examples
    ExamplesQL (28 tablets/28 days); QL (30 tablets/30 days); QL (4 tablets/365 days); QL (60 tablets/30 days); QL (360 tablets/30 days)
    VariationQuantity limits vary by formulation and pack size — some products list alternate QL by presentation (e.g., TRIUMEQ 30 or 360 tablets/30 days).
    Associated controlsThese QLs commonly accompany PA or SP flags for specialty/antiviral agents.
    Example entriesSTRIBILD QL 28 packets/28 days; TRIUMEQ QL 360 tablets/30 days (other formulation), MAVYRET QL 84 tablets/28 days.
    inv-39: Quantity limits examples
    Common QLs30 tablets/30 days; 60 tablets/30 days; 120 tablets/30 days; 28 packets/28 days (product-dependent)
    Product dependenceQuantity limits vary by product and strength — check the product line for the exact QL and time period.
    Typical periodMost QLs are defined per 28–30 day period, though some use 21, 90, 180, or 365 days for packs or specialty therapy.
    inv-40: Quantity limits examples
    ExamplesQL (120 capsules/30 days); QL (90 tablets/30 days); QL (60 tablets/30 days)
    Oncology/specialtyHigher capsule/tablet QLs (e.g., 120 capsules/30 days) are common in oncology/targeted therapy listings.
    Associated flagsThese QLs frequently appear with LD and PA for limited-distribution specialty agents.
    inv-41: Quantity Limits examples
    Specific examplesFARXIGA: QL 30 tablets/30 days; JANUMET: QL 60 tablets/30 days; OZEMPIC: QL 1 pen/28 days
    ActionObserve QL when prescribing GLP‑1 and antidiabetic agents; requests exceeding QL may require PA or be denied.
    DocumentationProvide supporting documentation for PA requests when QL and PA flags are present.
    inv-42: Quantity limits examples
    Range of QLsExamples include 210 tablets/30 days; 2400 mls/30 days; 4800 mls/30 days; 2520 mls/21 days; 1260 mls/21 days; 8 kits/180 days; 1800 mls/30 days
    Liquid formulationsLarge-volume oral solutions and suspensions list QLs in mLs per period (e.g., propranolol solutions with 2400 or 4800 mls/30 days).
    Kits/packsSome therapies use kit or cartridge limits (e.g., FUROSCIX 8 kits/180 days).
    inv-43: Quantity limits examples
    ExamplesREPATHA 6 syringes/28 days; NEXLETOL 30 tablets/30 days; VASCEPA 120–240 capsules/30 days; VYNDAMAX 30 capsules/30 days
    Cardiovascular/specialtyMany cardiovascular and lipid‑lowering specialty agents have QLs defined by syringes or capsule counts per 28–30 days.
    Specialty dispensingThese QLs often appear with PA and SP flags indicating specialty pharmacy handling.
    inv-44: Quantity limits (examples)
    Examples30 tablets/30 days; 1 syringe/28 days; 12 capsules/365 days; 180 tablets/30 days; 600 mls/30 days
    Clinical classesApplicable across GI, CNS, and other therapeutic classes — e.g., VELPHORO 180 tablets/30 days; aripiprazole solution 900 mls/30 days.
    Denial riskDispensing that exceeds these listed QLs may be denied unless PA is obtained and documented.
    inv-45: Prior Authorization required for some drugs
    Prior authorizationSome drugs require prior authorization (PA) before the plan will pay; entries marked 'PA' indicate this requirement.
    ImplicationFailure to obtain PA when required may result in denial of coverage for the drug.
    When QL presentQuantity limits (QL) listed for many products indicate caps that must be observed when submitting claims.
    inv-175: ARIKAYCE — 28 vials
    ARIKAYCE28 vials/28 days
    FlagsARIKAYCE listing includes LD, PA, QL and SP designations.
    SourceProduct line in formulary Requirements/Limits field specifies QL and accompanying flags.
    inv-176: itraconazole (caps) — 120 capsules
    itraconazole (caps)120 capsules/30 days
    FormulationsItraconazole oral solution has separate QL and PA (1200 mls/30 days with PA).
    ReferenceSee antifungals section for exact capsule and solution QLs.
    inv-177: MAVYRET (tab) — 84 tablets
    MAVYRET (tab)84 tablets/28 days
    ContextMAVYRET appears with PA and SP flags for hepatitis C treatment courses.
    Alternate packMAVYRET pellet pack has a different QL (140 packets/28 days) listed separately.
    inv-178: PAXLOVID — 11-30 tablets depending on pack size
    PAXLOVID11–30 tablets depending on pack size (QL varies by pack)
    NoteQL for PAXLOVID is specified per pack; check pack size when submitting claims.
    ExamplePAXLOVID QL recorded as 30 tablets/30 days for some presentations.
    inv-179: SUNLENCA — 4-5 tablets
    SUNLENCA4–5 tablets (therapy pack) or LD, QL 4 or 5 tablets/365 days depending on pack
    DistributionSUNLENCA is LD and SP; QL differs by 4‑tablet or 5‑tablet therapy pack.
    Prescribing noteObserve loading dose (LD) and annual QL when initiating therapy.
    inv-180: STRIBILD — 28 packets/28 days (alternate line: 30 tablets/30 days)
    STRIBILD28 packets/28 days (alternate listing: 30 tablets/30 days)
    Alternate formulationSome entries list packetized QL; alternate line shows 30 tablets/30 days for tablet presentation.
    Associated flagsSTRIBILD entry includes PA and SP flags in some presentations.
    inv-181: SUNLENCA — LD, QL (4 or 5 tablets/365 days depending on pack)
    SUNLENCA (LD)LD, QL 4 or 5 tablets/365 days depending on pack
    ImplicationLoading dose (LD) and annual QL require adherence to the specified pack-based limits.
    SpecialtySUNLENCA is managed as a specialty product (SP) with limited distribution.
    inv-182: TRIUMEQ — QL (30 tablets/30 days) or QL (360 tablets/30 days for other formulation)
    TRIUMEQQL 30 tablets/30 days or QL 360 tablets/30 days for other formulation
    Formulation noteDifferent presentations of TRIUMEQ have distinct QLs; confirm formulation when assessing supply.
    Provider actionEnsure dispensed quantity matches the listed QL and formulation to avoid denials.
    inv-183: VIREAD — QL (30 tablets/30 days) or QL (240 grams/30 days for powder)
    VIREADQL 30 tablets/30 days or QL 240 grams/30 days for powder
    Presentation-specificTablet and powder formulations have different QLs; use appropriate unit (tablets vs grams).
    Check line itemConfirm the exact formulation on the prescription to apply the correct QL.
    inv-184: XOFLUZA — QL (2 tablets/120 days)
    XOFLUZAQL 2 tablets/120 days
    Therapy packXOFLUZA listed as therapy pack with limited quantity over a 120‑day period.
    ImplicationPrescriptions exceeding this QL may be rejected without PA or justification.
    inv-185: zidovudine (capsules) — QL (180 capsules/30 days)
    zidovudine (capsules)QL 180 capsules/30 days
    Other formulationsZidovudine syrup and tablets have separate QLs (e.g., syrup 1920 mls/30 days; tablets QL 60 tablets/30 days for some strengths).
    HIV agentsZidovudine entries are part of HIV agents where QLs reflect chronic therapy supply.
    inv-186: nitazoxanide — QL (12 tablets/90 days)
    nitazoxanideQL 12 tablets/90 days
    Use caseNitazoxanide QL defined over a 90‑day period; check interval when dispensing.
    Formulary entryListed under anti-infectives with QL specified in Requirements/Limits.

    Dispensing Channel and Site-of-Care Notes

    Note
    Note
    Note
    Note
    Note
    Note

    Biosimilars and Related Notes

    Note

    Abbreviations and Definitions

    Step Therapy Rules and Notes

    Step therapy summarySupporting detail / guidance
    Step therapy (ST) may require trial of specified first-line drugs before coverage of an alternative agent.
    Per formulary definition: members may be required to try certain drugs first; exceptions can be requested and the member/ provider may discuss alternatives.
    Step therapy summarySupporting detail / guidance
    No explicit step-therapy sequences are provided in this excerpt.
    Product lines in this segment list Requirements/Limits entries (PA, QL, LD, SP) but do not define step sequences for specific agents.
    Step therapy summarySupporting detail / guidance
    No explicit step therapy sequences are listed in these chunks; explicit step controls are not present here.
    Listings show utilization flags (e.g., PA, QL, LD, SP) and QL values for products but do not provide ordered step requirements.
    Step-related flagImplication for coverage / distribution
    LD (Limited Distribution)
    Indicates limited distribution channel; product may be required to be dispensed via designated specialty pharmacy or restricted channel. (Examples: PALFORZIA, SUNLENCA list LD and SP).
    Loading dose (LD) notesImplication / coverage note
    Some medications indicate LD (loading dose) prior to regular fills.
    Formulary entries show LD for select products (e.g., SUNLENCA therapy packs; metoprolol entries include LD/PA/QL flags), but explicit multi-step sequences are not provided in this excerpt.
    Prior authorization (PA) presenceExamples / affected agents
    PA required prior to coverage for specified agents.
    Several GLP‑1 and related products are listed with PA (examples in this segment include MOUNJARO, OZEMPIC, TRULICITY showing PA and QL).
    ST flag presentExample
    'ST' annotation indicates step therapy may be required before coverage.
    KERENDIA is listed with 'ST' in the Requirements/Limits — indicating step therapy requirements apply per product listing.
    SP / ST flagsImplication
    Products annotated with SP or ST may have step or specialty program requirements prior to coverage.
    Examples: PALFORZIA and SUNLENCA include LD and SP; other entries show ST alongside QL (see various product lines).
    High-cost/specialty flagsCoverage implication
    Several specialty and high‑cost agents are flagged LD, PA, or SP suggesting step, limited distribution, or additional administrative processes before coverage.
    Formulary examples include oncology and specialty agents with LD/PA/SP and explicit QLs (e.g., LONSURF, LORBRENA, ALUNBRIG, ALYFTREK, and many others require LD/PA/QL/SP).
    Products with 'ST' notesExamples from formulary
    Certain products require step therapy prior to coverage as indicated by 'ST' in Requirements/Limits.
    Examples from the listing: VELPHORO includes 'ST'; FETZIMA, FLUOXETINE DR, TRINTELLIX, and other listed agents show 'ST' alongside QL in their Requirements/Limits entries.
    ST annotation meaningFormulary statement / examples
    Entries annotated 'ST' indicate step therapy is required before coverage of the listed product.
    Multiple psychotropic, GI and other products are marked ST in the formulary (e.g., FANAPT titration packs, BELSOMRA, DAYVIGO, and others have ST flags noted).
    LD and PA combinedImplication
    Some agents list LD and PA together, implying limited distribution and prior authorization are required before coverage.
    Examples include LUMRYZ and MAYZENT starter/maintenance packs where LD and PA (and QL) are shown for coverage control; explicit step sequences are not provided in the excerpt.
    ST noted for select NSAIDs/analgesicsExamples
    ST indicated for some NSAID/analgesic products, requiring prior trial of preferred agents.
    Formulary examples: KETOPROFEN ER and MECLOFENAMATE SODIUM are listed with 'ST' in their Requirements/Limits entries.

    Policy Background

    The formulary is an administrative listing of covered drugs with per-line utilization controls rather than clinical exclusion rules. Providers should follow the Requirements/Limits shown (for example, obtain PA when indicated or adhere to the stated QL) to support coverage.

    Policy Revision History